-
公开(公告)号：US11779602B2
公开(公告)日：2023-10-10
申请号：US16253562
申请日：2019-01-22
发明人： Philip Stewart Low , Haiyan Chu , Yingjuan June Lu , Christopher Paul Leamon , Leroy W. Wheeler, II , Michael C. Jensen , James Matthaei
IPC分类号： A61K35/17 , C07K14/725 , C12N5/0783 , A61P35/00 , A61K9/00 , A61K31/365 , A61K31/519 , A61K38/17 , C07K16/44 , C07K16/46
CPC分类号： A61K35/17 , A61K9/0019 , A61K9/0053 , A61K31/365 , A61K31/519 , A61K38/1774 , A61P35/00 , C07K14/7051 , C07K16/44 , C07K16/46 , C12N5/0638 , C07K2317/622
摘要： The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
-
公开(公告)号：US20240327521A1
公开(公告)日：2024-10-03
申请号：US18293330
申请日：2022-07-27
发明人： Michael C. Jensen , James Rosser
IPC分类号： C07K16/28 , A61K39/00 , C07K14/55 , C07K14/705 , C07K14/725 , C12N5/0783
CPC分类号： C07K16/2827 , A61K39/4611 , A61K39/4631 , A61K39/464411 , A61K39/464412 , C07K14/55 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K16/2803 , C12N5/0636 , A61K2239/15 , A61K2239/17 , A61K2239/22 , C07K2317/53 , C07K2317/622 , C07K2319/03 , C12N2510/00
摘要： Some embodiments of the methods and compositions provided herein include methods and/or systems for increasing an activity of a cell comprising a chimeric antigen receptor (CAR), comprising use of a first nucleic acid encoding a transcription response element (TRE); and a second nucleic acid encoding a CAR, wherein the activity of the cell is increased compared to a cell lacking the first nucleic acid. In some embodiments, the increased activity of the cell is selected from: (i) survival of a subject administered the cell, wherein the subject comprises a target cell comprising an antigen, wherein the CAR is capable of specifically binding to the antigen; (ii) killing of a target cell comprising an antigen, wherein the CAR is capable of specifically binding to the antigen; and (iii) proliferation of the cell in the presence of a target cell comprising an antigen, wherein the CAR is capable of specifically binding to the antigen.
-
公开(公告)号：US20230374104A1
公开(公告)日：2023-11-23
申请号：US18030476
申请日：2021-10-07
发明人： Michael C. Jensen , Adam Johnson , James Rosser
IPC分类号： C07K14/705 , C07K14/725
CPC分类号： C07K14/70596 , C07K14/7051
摘要： Some embodiments of the methods and compositions provided herein relate to chimeric proteins comprising a programmed cell death protein 1 (PD 1) extracellular domain and an intracellular immunostimulatory domain. Some embodiments include a cell containing a PD 1 chimeric polypeptide and a chimeric antigen receptor (CAR). In some embodiments, the CAR comprises a ligand binding domain capable of specifically binding to a target antigen on a solid tumor. More embodiments relate to therapies to treat, inhibit or ameliorate certain disorders, such as a cancer, such as a solid tumor.
-
公开(公告)号：US11760804B2
公开(公告)日：2023-09-19
申请号：US18061196
申请日：2022-12-02
发明人： Michael C. Jensen , Rebecca Gardner
CPC分类号： C07K16/2866 , A61K9/0019 , A61K9/0053 , A61P35/02 , A61K2039/505 , C07K2319/03
摘要： Provided are methods for preventing or ameliorating toxicity caused by or due to a therapy, such as an immunotherapy or a cell therapy, by pre-emptive or early administration toxicity-targeting agent(s). In some embodiments, the therapy is a cell therapy in which the cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the methods, including the timing of the administration of the agents or treatments for toxicity, provide various advantages, such as lower toxicity while maintaining persistence and efficacy of the administered cells.
-
公开(公告)号：US11649288B2
公开(公告)日：2023-05-16
申请号：US16480833
申请日：2018-02-06
发明人： Michael C. Jensen , James Matthaei
IPC分类号： A61K47/54 , A61K49/00 , C07K16/28 , C07K16/08 , C07K16/12 , C07K16/30 , C07K16/32 , A61P35/00 , G01N33/569 , A61K39/00 , C07K14/725
CPC分类号： C07K16/2809 , A61K47/544 , A61P35/00 , C07K16/08 , C07K16/12 , C07K16/30 , C07K16/32 , A61K49/0052 , A61K2039/5158 , C07K14/7051 , C07K2317/622 , C07K2319/03 , C07K2319/33
摘要： Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
-
公开(公告)号：US20230068879A1
公开(公告)日：2023-03-02
申请号：US17758959
申请日：2021-02-02
IPC分类号： C07K14/725
摘要： Embodiments provided herein include methods and compositions comprising anti-dinitrophenol chimeric antigen receptors (CARs). Some embodiments include nucleic acids encoding such CARs, polypeptides encoded by such nucleic acids, cells comprising such nucleic acids or polypeptides, and methods utilizing such cells. Some embodiments also include the use of dinitrophenol (DNP) and derivatives thereof.
-
公开(公告)号：US11458167B2
公开(公告)日：2022-10-04
申请号：US15750708
申请日：2016-08-03
发明人： Michael C. Jensen
IPC分类号： A61K35/17 , A61P35/00 , C07K14/725 , C07K14/705 , C07K16/30 , C07K16/28
摘要： Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.
-
公开(公告)号：US20220195441A1
公开(公告)日：2022-06-23
申请号：US17594542
申请日：2020-04-21
申请人： Seattle Children's Hospital (dba Seattle Children's Research Institute) , Fred Hutchinson Cancer Research Center
IPC分类号： C12N15/62 , C07K16/28 , C07K14/705 , C07K14/725 , C07K14/71
摘要： Some embodiments of the methods and compositions provided herein include chimeric antigen receptors (CAR)s which specifically bind to an epitope of CD33, such as an epitope encoded by exon 2 of CD33. Some embodiments include the use of such CARs for effective and safe therapies for myeloid leukemias, such as acute myeloid leukemia and chronic myeloid leukemia.
-
公开(公告)号：US20210317407A1
公开(公告)日：2021-10-14
申请号：US17265484
申请日：2019-08-02
IPC分类号： C12N5/0783 , A61K35/17 , C07K16/44 , C07K14/73 , C07K14/705 , C07K16/28
摘要： Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.
-
公开(公告)号：US20200377911A1
公开(公告)日：2020-12-03
申请号：US16740995
申请日：2020-01-13
发明人： Andrew M. Scharenberg , David J. Rawlings , Michael C. Jensen , Kamila Sabina Gwiazda , Alexandra E. Grier
IPC分类号： C12N15/90 , C12N15/86 , A61K38/46 , A61P35/00 , A61K48/00 , C12N7/04 , C12N15/113 , C12N15/861
摘要： Disclosed herein are nuclease-based systems for genome editing and methods of using the system for genome editing. Also, disclosed are approaches to enhance Cas9-mediated gene editing efficiency in primary human cells with minimal toxicity when using adeno-associated virus vectors (AAV) to express the guide RNAs necessary for CRISPR/Cas9-based genome editing in the presence of helper proteins.
-
-
-
-
-
-
-
-
-
搜索结果
77 条记录 (耗时 0.034 秒)
